Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT03983954 Active, not recruiting - Prostate Cancer Clinical Trials

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors

Start date: October 10, 2019
Phase: Phase 1
Study type: Interventional

This is a dose escalation, MTD expansion (Phase 1b) and cohort expansions (Phase 2) study to assess the safety and tolerability of a combination of NAP with durvalumab in subjects with selected advanced or metastatic solid tumors.

NCT ID: NCT03982407 Completed - Clinical trials for Hepatocellular Carcinoma

68 Ga PSMA PET/MRI for Hepatocellular Carcinoma

Start date: June 27, 2019
Phase: Early Phase 1
Study type: Interventional

This is a pilot study to investigate the evaluate to use of a drug/radiopharmaceutical called Gallium-68 PSMA-11 (68Ga-PSMA-11) for use in PET/MRI evaluation of hepatocellular carcinoma

NCT ID: NCT03981848 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Radiomics-based Non-invasive Classifier Research for HCC-related Liver Transplantation

Start date: July 2019
Phase:
Study type: Observational

The purpose of this study is to establish a non-invasive radiomics method to filter high recurrent-risk liver transplantation recipient population

NCT ID: NCT03979547 Terminated - Clinical trials for Hepatocellular Carcinoma

EXALT: EXercise Attenuates Liver Tumors Trial

EXALT
Start date: January 3, 2019
Phase: N/A
Study type: Interventional

The overall goal of this proposal is to test the effect of exercise to delay or avert HCC recurrence and gain information regarding the potential molecular mechanisms of HCC tumor inhibition by exercise.

NCT ID: NCT03974074 Recruiting - Clinical trials for Hepatocellular Carcinoma

Albumin for Hepatocellular Carcinoma

Start date: March 1, 2019
Phase: Phase 3
Study type: Interventional

The rate of liver cirrhosis is about 40% to 75% among patients with hepatocellular carcinoma (HCC). Therefore, many patients with HCC were with low serum albumin before and after (especially) hepatic resection. Serum albumin level has been routinely used in clinical practice as a surrogate marker to evaluate nutritional status and liver function. Serum albumin concentration is used as an independent mortality risk predictor in a broad range of clinical and research settings. However, the role of albumin infusion in patients with hepatocellular carcinoma (HCC) after resection is unknown. The present study aimed to investigate the safety and clinical necessity of albumin infusion for HCC patients after hepatic resection.

NCT ID: NCT03973112 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients

Start date: September 24, 2019
Phase: Phase 2
Study type: Interventional

This trial is a single-arm, open, multicenter phase II clinical study.Subjects can only enter this study after they meet the inclusion and exclusion criteria.Into subjects will accept HLX10 + HLX04 intravenous infusion, every two weeks, lose treatment until clinical benefit, toxicity, the subjects of the resistance or the doctor decided to suspend the treatment, tested subjects death revocation of informed consent, subjects, subjects of pregnancy, not to plan or program requirement from, or management reasons, treatment for up to 2 years (before).

NCT ID: NCT03971747 Recruiting - Clinical trials for Hepatocellular Carcinoma

AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma

Start date: August 6, 2019
Phase: Phase 1
Study type: Interventional

A phase 1 study that aimed to assess the safety and anti-tumor activity of C-TCR055 injection in unresectable HCC patients.

NCT ID: NCT03970616 Terminated - Clinical trials for Hepatocellular Carcinoma

A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma

DEDUCTIVE
Start date: September 30, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability, DLTs, MTD, and preliminary anti tumor activity of tivozanib in combination with durvalumab in subjects with advanced HCC.

NCT ID: NCT03969576 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)

Start date: September 15, 2020
Phase: N/A
Study type: Interventional

this multi-center prospective cohort study is to evaluate the efficacy and the safety of drug-eluting bead TACE compared with conventional TACE in terms of objective response in unresectable HCC

NCT ID: NCT03966209 Recruiting - Clinical trials for Hepatocellular Carcinoma

Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant

Start date: May 1, 2019
Phase: Phase 1
Study type: Interventional

This is a perspective clinical study to assess the safety and efficacy of PD-1 inhibitors in patients with LT. Eligible patients have recurrent or metastatic cancer after LT, are not amenable to, or refractory after, locoregional therapy or to a curative treatment approach (eg, surgery, or ablation) and have previously been treated with sorafenib or other targeted therapy, either intolerant to this treatment or show radiographic progression after treatment. Biopsy is needed to exclude patients with positive allograft PD-L1 expression.